Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study

Bokemeyer B, Plachta-Danielzik S, Di Giuseppe R, Deppe H, Mohl W, Teich N, Hoffstadt M, Schweitzer A, Von Der Ohe M, Gauss A, Atreya R, Krause T, Blumenstein I, Hoechstoedter J, Hartmann P, Schreiber S (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Journal of Crohns & Colitis Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: I534-I535

Conference Proceedings Title: JOURNAL OF CROHNS & COLITIS

DOI: 10.1093/ecco-jcc/jjab232.727

Authors with CRIS profile

Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen

Involved external institutions

Universitätsklinikum Heidelberg DE Germany (DE) Competence Network IBD DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) DE Germany (DE)

How to cite

APA:

Bokemeyer, B., Plachta-Danielzik, S., Di Giuseppe, R., Deppe, H., Mohl, W., Teich, N.,... Schreiber, S. (2022). Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study. In JOURNAL OF CROHNS & COLITIS (pp. I534-I535). OXFORD: OXFORD UNIV PRESS.

MLA:

Bokemeyer, B., et al. "Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study." Proceedings of the JOURNAL OF CROHNS & COLITIS OXFORD: OXFORD UNIV PRESS, 2022. I534-I535.

BibTeX: Download